Evidence map›Paper›PMID 40405710›Full record

SynthesisMuscle & nerve2025

A Systematic Review of Attributes Influencing Preferences for Treatments and Interventions in People With Amyotrophic Lateral Sclerosis (ALS).

A Clift, D Rowen, L Knox, A W Griffiths, C J McDermott

Abstract readSystematic Review
In one paragraph

Synthesis in Muscle & nerve, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A CliftSheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0009-0004-9620-6325
D RowenSheffield Centre for Health and Related Research, University of Sheffield, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK.
L KnoxSheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.
A W GriffithsSheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.
C J McDermottSheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.

Funding

National Institute for Health and Care Research
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that has no cure, and treatments predominantly focus on improving quality of life. Patient-centred care is central to bringing about meaningful improvements to quality of life. This review addresses the lack of consolidated evidence on what matters most to people with ALS (pwALS) by synthesizing 44 preference-based studies covering six different treatment and intervention categories. Data-based convergent synthesis identified five overarching factors influencing preferences: ease of use, accessibility, making life easier, autonomy, and safety/reliability. Simplifying and enhancing accessibility of treatment delivery across disease stages aligns with the nature of neurodegenerative disorders such as ALS, where function declines as the disease progresses. The value in perceived and real control reflects the profound impact ALS has on an individual's independence. Safety and reliability are crucial for people with ALS and are recognized as fundamental requirements for quality healthcare. The themes identified in this review can inform the attributes of preference elicitation methods. Systematically varying the levels of these attributes elicits quantitative measures of preferences. These findings can be used to inform and develop healthcare policy and clinical practice in ALS care. Specifically, preferences related to drug treatments can then be integrated into target product profiles (TPPs) to align drug development with the needs and values of pwALS. Integrating patient preferences into clinical practice promotes patient-centred care, increasing both patient satisfaction and treatment effectiveness.

Indexed as

Amyotrophic Lateral SclerosisPatient PreferenceHumansPatient-Centered CareQuality of LifeALSinterventionsMNDpreferencestreatmentsviews

Identifiers

PMID40405710
PMCPMC12338022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.